医学
急性肾损伤
糖尿病
重症监护医学
糖尿病肾病
并发症
不利影响
肾脏疾病
肾病
造影剂肾病
2型糖尿病
内科学
生物信息学
内分泌学
生物
作者
Annunziata Nusca,Francesco Piccirillo,Michele Viscusi,Sara Giannone,Fabio Mangiacapra,Rosetta Melfi,Elisabetta Ricottini,Gian Paolo Ussia,Francesco Grigioni
出处
期刊:Journal of Cardiovascular Pharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2022-11-01
卷期号:80 (5): 661-671
被引量:5
标识
DOI:10.1097/fjc.0000000000001329
摘要
Contrast-induced acute kidney injury (CI-AKI) is a serious complication in patients undergoing diagnostic or therapeutic procedures that require contrast use and negatively affects the long-term outcomes. Patients with type 2 diabetes mellitus (DM), particularly those who have already developed diabetic nephropathy (DN), are more susceptible to contrast-induced renal damage. Indeed, contrast media amplify some pathological molecular and cellular pathways already in place in the DN setting. In recent years, sodium–glucose cotransporter-2 inhibitors (SGLT2i) have triggered a paradigm shift in managing patients with type 2 DM, reducing cardiovascular and renal adverse events, and slowing DN development. Some evidence also suggests favorable effects of SGLT2i on acute kidney injury despite the initial alarm; however, little data exist regarding CI-AKI. The present review provides an updated overview of the most recent experimental and clinical studies investigating the beneficial effects of SGLT2i on chronic and acute renal injury, focusing on their potential role in the development of CI-AKI. Thus, we aimed to expand the clinicians' understanding by underscoring new opportunities to prevent this complication in the setting of DM, where effective preventive strategies are still lacking.
科研通智能强力驱动
Strongly Powered by AbleSci AI